Cargando…
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada
BACKGROUND: Depot formulations of antipsychotics provide a potential solution to the poor adherence to oral therapies in schizophrenia. However, there have been few comparative studies on the effectiveness and tolerability of first and second generation depot antipsychotics in a real clinical practi...
Autores principales: | Lammers, Laura, Zehm, Bree, Williams, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669627/ https://www.ncbi.nlm.nih.gov/pubmed/23718192 http://dx.doi.org/10.1186/1471-244X-13-155 |
Ejemplares similares
-
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013) -
Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015) -
Comparison of cost-effectiveness of long-acting depot injection antipsychotics and oral antipsychotics in patients with schizophrenia in a rural community in South India
por: Raghavan, Vijaya, et al.
Publicado: (2020) -
Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
por: Williams, Richard, et al.
Publicado: (2014) -
Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic
por: Chue, Pierre
Publicado: (2007)